{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T14:49:01Z","timestamp":1785163741075,"version":"3.55.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Frozen section evaluation can be used for intraoperative diagnosis of sentinel lymph node (SLN) metastases. When completion axillary lymph node dissection is planned owing to positive SLNs following neoadjuvant chemotherapy (NACT), frozen section may be considered to facilitate completion of axillary surgery at the index operation. The utility of intraoperative SLN assessment with frozen section in patients with hormone receptor-positive (HR\n                      <jats:sup>+<\/jats:sup>\n                      ) breast cancer depends on the prevalence of SLN positivity and frozen section accuracy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a single-institution observational cohort study including patients with noninflammatory, cN0, HR\n                      <jats:sup>+<\/jats:sup>\n                      , defined as either estrogen receptor-positive (ER\n                      <jats:sup>+<\/jats:sup>\n                      ) and\/or progesterone receptor-positive (PR\n                      <jats:sup>+<\/jats:sup>\n                      ), HER2-negative breast cancer treated with NACT between 2015 and 2021. We estimated the prevalence of SLN positivity and the diagnostic test characteristics of SLN frozen section.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 145 eligible patients, 47 (32.4%; 95% confidence interval [CI]: 24.9, 40.7) had SLN metastases. Positive SLNs were more frequent among those with ER\n                      <jats:sup>+<\/jats:sup>\n                      PR\n                      <jats:sup>+<\/jats:sup>\n                      tumors compared with ER\n                      <jats:sup>+<\/jats:sup>\n                      PR\n                      <jats:sup>\u2212<\/jats:sup>\n                      or ER\n                      <jats:sup>\u2212<\/jats:sup>\n                      PR\n                      <jats:sup>+<\/jats:sup>\n                      tumors, larger clinical T category, and invasive lobular histology. Among 115 patients with SLNs assessed by frozen section, the true prevalence of metastases was 31.3% (95% CI: 23.0, 40.6), while frozen section identified only 17.4% (95% CI: 11.0, 25.6) as positive. Frozen section sensitivity was 55.6% (95% CI: 38.1, 72.1), and specificity was 100% (95% CI: 95.4, 100.0). Sensitivity for micrometastases or isolated tumor cells was limited (23.5%; 95% CI: 6.8, 50.0).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      In patients with cN0 HR\n                      <jats:sup>+<\/jats:sup>\n                      , HER2-negative breast cancer, SLN positivity after NACT varies and is more common in high-risk subgroups of this population. Frozen section has modest sensitivity overall and is more limited for the diagnosis of low-volume nodal disease. Use of frozen section may be warranted where avoiding reoperation is a priority.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-026-19783-y","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T16:40:10Z","timestamp":1778776810000},"page":"7237-7243","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Sentinel Lymph Node Positivity and Utility of Frozen Section Diagnosis following Neoadjuvant Therapy in Patients with Clinically Node-Negative, Hormone Receptor-Positive, HER2-Negative Breast Cancer"],"prefix":"10.1245","volume":"33","author":[{"given":"Kerollos Nashat","family":"Wanis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rrita","family":"Krasniqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susie X.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Resetkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa F.","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly K.","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalind P.","family":"Candelaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puneet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"issue":"2","key":"19783_CR1","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s10549-014-3161-x","volume":"148","author":"JS Poling","year":"2014","unstructured":"Poling JS, Tsangaris TN, Argani P, Cimino-Mathews A. Frozen section evaluation of breast carcinoma sentinel lymph nodes: a retrospective review of 1,940 cases. Breast Cancer Res Treat. 2014;148(2):355\u201361. https:\/\/doi.org\/10.1007\/s10549-014-3161-x.","journal-title":"Breast Cancer Res Treat."},{"issue":"27","key":"19783_CR2","doi-asserted-by":"publisher","first-page":"3056","DOI":"10.1200\/JCO.21.00934","volume":"39","author":"M Brackstone","year":"2021","unstructured":"Brackstone M, Baldassarre FG, Perera FE, et al. Management of the axilla in early-stage breast cancer: Ontario health (cancer care Ontario) and ASCO GUIDELINE. JCO. 2021;39(27):3056\u201382. https:\/\/doi.org\/10.1200\/JCO.21.00934.","journal-title":"JCO."},{"issue":"2","key":"19783_CR3","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/cncr.25606","volume":"117","author":"L Liu","year":"2011","unstructured":"Liu L, Lang JE, Lu Y, et al. Intraoperative frozen section analysis of sentinel lymph nodes in breast cancer patients: a meta-analysis and single-institution experience. Cancer. 2011;117(2):250\u20138. https:\/\/doi.org\/10.1002\/cncr.25606.","journal-title":"Cancer"},{"issue":"10","key":"19783_CR4","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1097\/PAS.0000000000001311","volume":"43","author":"A Grabenstetter","year":"2019","unstructured":"Grabenstetter A, Moo TA, Hajiyeva S, et al. Accuracy of intraoperative frozen section of sentinel lymph nodes after neoadjuvant chemotherapy for breast carcinoma. Am J Surg Pathol. 2019;43(10):1377\u201383. https:\/\/doi.org\/10.1097\/PAS.0000000000001311.","journal-title":"Am J Surg Pathol."},{"issue":"8","key":"19783_CR5","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S1470-2045(06)70796-3","volume":"7","author":"IJ Bleiweiss","year":"2006","unstructured":"Bleiweiss IJ. Sentinel lymph nodes in breast cancer after 10 years: rethinking basic principles. Lancet Oncol. 2006;7(8):686\u201392. https:\/\/doi.org\/10.1016\/S1470-2045(06)70796-3.","journal-title":"Lancet Oncol."},{"issue":"8","key":"19783_CR6","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1245\/s10434-010-0952-0","volume":"17","author":"P Gimbergues","year":"2010","unstructured":"Gimbergues P, Dauplat MM, Durando X, et al. Intraoperative imprint cytology examination of sentinel lymph nodes after neoadjuvant chemotherapy in breast cancer patients. Ann Surg Oncol. 2010;17(8):2132\u20137. https:\/\/doi.org\/10.1245\/s10434-010-0952-0.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"19783_CR7","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/tbj.12829","volume":"24","author":"CL Akay","year":"2018","unstructured":"Akay CL, Albarracin C, Torstenson T, et al. Factors impacting the accuracy of intra-operative evaluation of sentinel lymph nodes in breast cancer. Breast J. 2018;24(1):28\u201334. https:\/\/doi.org\/10.1111\/tbj.12829.","journal-title":"Breast J."},{"issue":"11","key":"19783_CR8","doi-asserted-by":"publisher","first-page":"7339","DOI":"10.1245\/s10434-024-15712-z","volume":"31","author":"KN Wanis","year":"2024","unstructured":"Wanis KN, Goetz L, So A, et al. The prevalence of sentinel lymph node positivity and implications for the utility of frozen section diagnosis following neoadjuvant systemic therapy in patients with clinically node-negative HER2-positive or triple-negative breast cancer. Ann Surg Oncol. 2024;31(11):7339\u201346. https:\/\/doi.org\/10.1245\/s10434-024-15712-z.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"19783_CR9","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/bjs.7229","volume":"98","author":"DM Layfield","year":"2011","unstructured":"Layfield DM, Agrawal A, Roche H, Cutress RI. Intraoperative assessment of sentinel lymph nodes in breast cancer. Br J Surg. 2011;98(1):4\u201317. https:\/\/doi.org\/10.1002\/bjs.7229.","journal-title":"Br J Surg."},{"issue":"8","key":"19783_CR10","doi-asserted-by":"publisher","first-page":"791","DOI":"10.5858\/arpa.2015-0140-RA","volume":"140","author":"A Maguire","year":"2016","unstructured":"Maguire A, Brogi E. Sentinel lymph nodes for breast carcinoma: a paradigm shift. Arch Pathol Lab Med. 2016;140(8):791\u20138. https:\/\/doi.org\/10.5858\/arpa.2015-0140-RA.","journal-title":"Arch Pathol Lab Med."},{"key":"19783_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpi.2022.100092","volume":"13","author":"V McMurtry","year":"2022","unstructured":"McMurtry V, Poretta JM, Factor RE. After neoadjuvant therapy, axillary sentinel lymph node frozen sections from breast cancer patients are accurately diagnosed using telepathology. J Pathol Inform. 2022;13:100092. https:\/\/doi.org\/10.1016\/j.jpi.2022.100092.","journal-title":"J Pathol Inform"},{"issue":"16","key":"19783_CR12","doi-asserted-by":"publisher","first-page":"5678","DOI":"10.1158\/1078-0432.CCR-04-2421","volume":"11","author":"R Rouzier","year":"2005","unstructured":"Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005;11(16):5678\u201385. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-2421.","journal-title":"Clin Cancer Res."},{"issue":"4","key":"19783_CR13","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1097\/SLA.0000000000002953","volume":"268","author":"OM Fayanju","year":"2018","unstructured":"Fayanju OM, Ren Y, Thomas SM, et al. The clinical significance of breast-only and node-only pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT): a review of 20,000 breast cancer patients in the National Cancer Data Base (NCDB). Ann Surg. 2018;268(4):591\u2013601. https:\/\/doi.org\/10.1097\/SLA.0000000000002953.","journal-title":"Ann Surg."},{"issue":"12","key":"19783_CR14","doi-asserted-by":"publisher","first-page":"3902","DOI":"10.1245\/s10434-019-07643-x","volume":"26","author":"S Samiei","year":"2019","unstructured":"Samiei S, Van Kaathoven BN, Boersma L, et al. Risk of positive sentinel lymph node after neoadjuvant systemic therapy in clinically node-negative breast cancer: implications for postmastectomy radiation therapy and immediate breast reconstruction. Ann Surg Oncol. 2019;26(12):3902\u20139. https:\/\/doi.org\/10.1245\/s10434-019-07643-x.","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"19783_CR15","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1245\/s10434-024-16382-7","volume":"32","author":"A So","year":"2025","unstructured":"So A, Yi M, Simons JM, et al. Significance of residual nodal disease in clinically node-negative breast cancer after neoadjuvant chemotherapy. Ann Surg Oncol. 2025;32(2):922\u201330. https:\/\/doi.org\/10.1245\/s10434-024-16382-7.","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"19783_CR16","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1245\/s10434-017-6263-y","volume":"25","author":"Z Al-Hilli","year":"2018","unstructured":"Al-Hilli Z, Hoskin TL, Day CN, Habermann EB, Boughey JC. Impact of neoadjuvant chemotherapy on nodal disease and nodal surgery by tumor subtype. Ann Surg Oncol. 2018;25(2):482\u201393. https:\/\/doi.org\/10.1245\/s10434-017-6263-y.","journal-title":"Ann Surg Oncol."},{"key":"19783_CR17","doi-asserted-by":"publisher","unstructured":"Li X (Bill), Krishnamurti U, Bhattarai S, et al. Biomarkers predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer. Am J Clin Pathol. 2016;145(6):871-878. https:\/\/doi.org\/10.1093\/ajcp\/aqw045.","DOI":"10.1093\/ajcp\/aqw045"},{"issue":"5","key":"19783_CR18","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1002\/jso.26096","volume":"122","author":"MR Boland","year":"2020","unstructured":"Boland MR, Ryan \u00c9J, Nugent T, et al. Impact of progesterone receptor status on response to neoadjuvant chemotherapy in estrogen receptor-positive breast cancer patients. J Surg Oncol. 2020;122(5):861\u20138. https:\/\/doi.org\/10.1002\/jso.26096.","journal-title":"J Surg Oncol."},{"issue":"1","key":"19783_CR19","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1186\/s12957-022-02787-9","volume":"20","author":"D Guan","year":"2022","unstructured":"Guan D, Jie Q, Wu Y, Xu Y, Hong W, Meng X. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China. World J Surg Onc. 2022;20(1):326. https:\/\/doi.org\/10.1186\/s12957-022-02787-9.","journal-title":"World J Surg Onc."},{"issue":"15","key":"19783_CR20","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","volume":"30","author":"G Von Minckwitz","year":"2012","unstructured":"Von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. JCO. 2012;30(15):1796\u2013804. https:\/\/doi.org\/10.1200\/JCO.2011.38.8595.","journal-title":"JCO."},{"issue":"5","key":"19783_CR21","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1097\/SLA.0000000000001778","volume":"265","author":"E Tummel","year":"2017","unstructured":"Tummel E, Ochoa D, Korourian S, et al. Does axillary reverse mapping prevent lymphedema after lymphadenectomy? Ann Surg. 2017;265(5):987\u201392. https:\/\/doi.org\/10.1097\/SLA.0000000000001778.","journal-title":"Ann Surg."},{"issue":"4","key":"19783_CR22","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1097\/SLA.0000000000005952","volume":"278","author":"M Coriddi","year":"2023","unstructured":"Coriddi M, Dayan J, Bloomfield E, et al. Efficacy of immediate lymphatic reconstruction to decrease incidence of breast cancer-related lymphedema: preliminary results of randomized controlled trial. Ann Surg. 2023;278(4):630\u20137. https:\/\/doi.org\/10.1097\/SLA.0000000000005952.","journal-title":"Ann Surg."},{"issue":"1","key":"19783_CR23","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13058-024-01874-x","volume":"26","author":"J Lee","year":"2024","unstructured":"Lee J, Park S, Bae SJ, et al. Micrometastases in axillary lymph nodes in breast cancer, post-neoadjuvant systemic therapy. Breast Cancer Res. 2024;26(1):120. https:\/\/doi.org\/10.1186\/s13058-024-01874-x.","journal-title":"Breast Cancer Res."},{"issue":"1","key":"19783_CR24","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s10549-017-4157-0","volume":"163","author":"TJA Van Nijnatten","year":"2017","unstructured":"Van Nijnatten TJA, Simons JM, Moossdorff M, et al. Prognosis of residual axillary disease after neoadjuvant chemotherapy in clinically node-positive breast cancer patients: isolated tumor cells and micrometastases carry a better prognosis than macrometastases. Breast Cancer Res Treat. 2017;163(1):159\u201366. https:\/\/doi.org\/10.1007\/s10549-017-4157-0.","journal-title":"Breast Cancer Res Treat."},{"issue":"7","key":"19783_CR25","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1200\/JCO.24.01052","volume":"43","author":"G Montagna","year":"2025","unstructured":"Montagna G, Laws A, Ferrucci M, et al. Nodal burden and oncologic outcomes in patients with residual isolated tumor cells after neoadjuvant chemotherapy (ypN0i+): the OPBC-05\/ICARO study. JCO. 2025;43(7):810\u201320. https:\/\/doi.org\/10.1200\/JCO.24.01052.","journal-title":"JCO."},{"issue":"11","key":"19783_CR26","doi-asserted-by":"publisher","first-page":"3502","DOI":"10.1245\/s10434-019-07517-2","volume":"26","author":"SM Wong","year":"2019","unstructured":"Wong SM, Almana N, Choi J, et al. Prognostic significance of residual axillary nodal micrometastases and isolated tumor cells after neoadjuvant chemotherapy for breast cancer. Ann Surg Oncol. 2019;26(11):3502\u20139. https:\/\/doi.org\/10.1245\/s10434-019-07517-2.","journal-title":"Ann Surg Oncol."},{"key":"19783_CR27","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jss.2023.08.004","volume":"292","author":"GB Peery","year":"2023","unstructured":"Peery GB, Pak J, Burkbauer L, et al. Omission of axillary dissection in node positive breast cancer after neoadjuvant systemic therapy. J Surg Res. 2023;292:247\u201357. https:\/\/doi.org\/10.1016\/j.jss.2023.08.004.","journal-title":"J Surg Res."},{"issue":"6","key":"19783_CR28","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1001\/jamaoncol.2024.0578","volume":"10","author":"G Montagna","year":"2024","unstructured":"Montagna G, Mrdutt MM, Sun SX, et al. Omission of axillary dissection following nodal downstaging with neoadjuvant chemotherapy. JAMA Oncol. 2024;10(6):793. https:\/\/doi.org\/10.1001\/jamaoncol.2024.0578.","journal-title":"JAMA Oncol."},{"issue":"13","key":"19783_CR29","doi-asserted-by":"publisher","first-page":"8813","DOI":"10.1245\/s10434-024-16143-6","volume":"31","author":"JN Limberg","year":"2024","unstructured":"Limberg JN, Jones T, Thomas SM, et al. Omission of axillary lymph node dissection in patients with residual nodal disease after neoadjuvant chemotherapy. Ann Surg Oncol. 2024;31(13):8813\u201320. https:\/\/doi.org\/10.1245\/s10434-024-16143-6.","journal-title":"Ann Surg Oncol."},{"issue":"11","key":"19783_CR30","doi-asserted-by":"publisher","first-page":"6401","DOI":"10.1245\/s10434-023-13759-y","volume":"30","author":"JC Boughey","year":"2023","unstructured":"Boughey JC, Yu H, Dugan CL, et al. Changes in surgical management of the axilla over 11 years \u2013 Report on more than 1500 breast cancer patients treated with neoadjuvant chemotherapy on the prospective I-SPY2 trial. Ann Surg Oncol. 2023;30(11):6401\u201310. https:\/\/doi.org\/10.1245\/s10434-023-13759-y.","journal-title":"Ann Surg Oncol."},{"key":"19783_CR31","doi-asserted-by":"publisher","first-page":"1184021","DOI":"10.3389\/fonc.2023.1184021","volume":"13","author":"A Garcia-Tejedor","year":"2023","unstructured":"Garcia-Tejedor A, Ortega-Exposito C, Salinas S, et al. Axillary lymph node dissection versus radiotherapy in breast cancer with positive sentinel nodes after neoadjuvant therapy (ADARNAT trial). Front Oncol. 2023;13:1184021. https:\/\/doi.org\/10.3389\/fonc.2023.1184021.","journal-title":"Front Oncol."},{"issue":"4","key":"19783_CR32","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1001\/jamaoncol.2016.4163","volume":"3","author":"M Pilewskie","year":"2017","unstructured":"Pilewskie M, Morrow M. Axillary nodal management following neoadjuvant chemotherapy: a review. JAMA Oncol. 2017;3(4):549. https:\/\/doi.org\/10.1001\/jamaoncol.2016.4163.","journal-title":"JAMA Oncol."},{"issue":"15","key":"19783_CR33","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1002\/cncr.29348","volume":"121","author":"SS Mougalian","year":"2015","unstructured":"Mougalian SS, Soulos PR, Killelea BK, et al. Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States. Cancer. 2015;121(15):2544\u201352. https:\/\/doi.org\/10.1002\/cncr.29348.","journal-title":"Cancer."},{"issue":"12","key":"19783_CR34","doi-asserted-by":"publisher","first-page":"e84535","DOI":"10.1371\/journal.pone.0084535","volume":"8","author":"AA Onitilo","year":"2013","unstructured":"Onitilo AA, Onesti JK, Single RM, et al. Utilization of neoadjuvant chemotherapy varies in the treatment of women with invasive breast cancer. PLoS ONE. 2013;8(12):e84535. https:\/\/doi.org\/10.1371\/journal.pone.0084535.","journal-title":"PLoS ONE."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19783-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-19783-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19783-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T13:40:02Z","timestamp":1783345202000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-19783-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["19783"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-19783-y","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"assertion":[{"value":"18 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}